Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
Ashley M HopkinsAkash D RathodAndrew RowlandGanessan KichenadasseMichael J SorichPublished in: BMC cancer (2020)
Females had approximately two-fold increased risk of developing severe rash compared to males in clinical trials of vemurafenib alone or in combination with cobimetinib.